Amgen has expanded its R&D license agreement with Selexis SA to include an evaluation of Selexis’ SURE CHO-M Cell Line for R&D. Amgen will be able to evaluate the SURE CHO-M Cell Line in conjunction with the Selexis SUREtech Vectors for improved R&D.
"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch, Ph.D., president and chief executive officer of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently. This current agreement is built on the long-standing relationship between our two companies since 2004."
Amgen, Selexis Expand R&D License Agreement
Published February 20, 2013
blog comments powered by Disqus